Paper36976323
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.
Yashar WM and 14 others. Mol Cancer Res, 2023. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia. Papers, record 36976323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36976323
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| fms-Like Tyrosine Kinase 3 | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Humans | |
| Apoptosis | |
| Histone Demethylases | |
| Mutation | |
| Protein Kinase Inhibitors | |
| STAT5 Transcription Factor |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 GM109835 | NIGMS NIH HHS | United States | T32GM109835 | PubMed and NIH | NIH RePORTER |
| P30 CA016672 | NCI NIH HHS | United States | P30CA016672 | PubMed and NIH | NIH RePORTER |
| K08 CA245224 | NCI NIH HHS | United States | K08CA245224 | PubMed and NIH | NIH RePORTER |
| R01 CA247943 | NCI NIH HHS | United States | R01CA247943 | PubMed and NIH | NIH RePORTER |
| U54 CA224019 | NCI NIH HHS | United States | U54CA224019 | PubMed and NIH | NIH RePORTER |
| R01 CA065823 | NCI NIH HHS | United States | R01CA065823 | PubMed and NIH | NIH RePORTER |
| R01 CA282133 | NCI NIH HHS | United States | R01CA282133 | PubMed | NIH RePORTER |
| P30 CA069533 | NCI NIH HHS | United States | P30CA069533 | PubMed | NIH RePORTER |
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33148262 | The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. | Mol Cancer | 2020 | https://conductscience.org/library/papers/33148262 | PubMed |
| 2 | 9694804 | PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. | Genes Dev | 1998 | https://conductscience.org/library/papers/9694804 | PubMed |
| 3 | 15620353 | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. | Cell | 2004 | https://conductscience.org/library/papers/15620353 | PubMed |
| 4 | 25982114 | BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. | Mol Cell | 2015 | https://conductscience.org/library/papers/25982114 | PubMed |
| 5 | 29706549 | Integrated Single-Cell Analysis Maps the Continuous Regulatory Landscape of Human Hematopoietic Differentiation. | Cell | 2018 | https://conductscience.org/library/papers/29706549 | PubMed |
| 6 | 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 | https://conductscience.org/library/papers/30333627 | PubMed |
| 7 | 30420889 | The Myc/Max/Mxd Network Is a Target of Mutated Flt3 Signaling in Hematopoietic Stem Cells in Flt3-ITD-Induced Myeloproliferative Disease. | Stem Cells Int | 2018 | https://conductscience.org/library/papers/30420889 | PubMed |
| 8 | 36259537 | Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. | Elife | 2022 | https://conductscience.org/library/papers/36259537 | PubMed |
| 9 | 17277777 | Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. | Nat Genet | 2007 | https://conductscience.org/library/papers/17277777 | PubMed |
| 10 | 25684206 | A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation. | Mol Cell | 2015 | https://conductscience.org/library/papers/25684206 | PubMed |
| 11 | 31036827 | CUT&Tag for efficient epigenomic profiling of small samples and single cells. | Nat Commun | 2019 | https://conductscience.org/library/papers/31036827 | PubMed |
| 12 | 16885027 | Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. | Mol Cell | 2006 | https://conductscience.org/library/papers/16885027 | PubMed |
| 13 | 35590033 | PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia. | Leukemia | 2022 | https://conductscience.org/library/papers/35590033 | PubMed |
| 14 | 17686054 | Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. | Br J Haematol | 2007 | https://conductscience.org/library/papers/17686054 | PubMed |
| 15 | 28079019 | An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. | Elife | 2017 | https://conductscience.org/library/papers/28079019 | PubMed |
| 16 | 29590629 | Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. | Cell Rep | 2018 | https://conductscience.org/library/papers/29590629 | PubMed |
| 17 | 21106759 | Histone H3K27ac separates active from poised enhancers and predicts developmental state. | Proc Natl Acad Sci U S A | 2010 | https://conductscience.org/library/papers/21106759 | PubMed |
| 18 | 20434979 | Regulation of RNA polymerase II elongation by c-Myc. | Cell | 2010 | https://conductscience.org/library/papers/20434979 | PubMed |
| 19 | 29453291 | LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. | Blood | 2018 | https://conductscience.org/library/papers/29453291 | PubMed |
| 20 | 28159741 | Biology and relevance of human acute myeloid leukemia stem cells. | Blood | 2017 | https://conductscience.org/library/papers/28159741 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42139346 | P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML. | Sci Adv | 2026 | https://conductscience.org/library/papers/42139346 | PubMed |
| 42129910 | KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibition. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/42129910 | PubMed |
| 41301700 | Drug Repurposing for AML: Structure-Based Virtual Screening and Molecular Simulations of FDA-Approved Compounds with Polypharmacological Potential. | Biomedicines | 2025 | https://conductscience.org/library/papers/41301700 | PubMed |
| 40940894 | The Targeted Inhibition of Histone Lysine Demethylases as a Novel Promising Anti-Cancer Therapeutic Strategy-An Update on Recent Evidence. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940894 | PubMed |
| 38455978 | Predicting transcription factor activity using prior biological information. | iScience | 2024 | https://conductscience.org/library/papers/38455978 | PubMed |
Genes31
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36976323
GET https://conductscience.org/api/papers/v1/36976323/references?page=2